A Two-Part, Double-Blind, Placebo-Controlled, Single- and Multiple-Dose (Part A) or Twice Daily Dose (Part B) Study of AGN-241751 in Adult Participants With Major Depressive Disorder
Phase of Trial: Phase I/II
Latest Information Update: 17 Jan 2020
Price : $35 *
At a glance
- Drugs AGN-241751 (Primary)
- Indications Major depressive disorder
- Focus Therapeutic Use
- Sponsors Allergan; Naurex
- 12 Dec 2019 Status changed from active, no longer recruiting to completed.
- 08 Oct 2019 Planned End Date changed from 16 May 2019 to 24 Oct 2019.
- 08 Oct 2019 Planned primary completion date changed from 16 May 2019 to 24 Oct 2019.